Rare oncology and clinical operations

Rezolute’s upLIFT Result: Ersodetug, Glucose Support and Trial Evidence

What Rezolute’s preliminary Phase 3 upLIFT findings mean for tumor-related hypoglycemia, glucose-support endpoints and oncology trial operations.

By Lampgen Clinical Research

Illustrative infusion equipment beside a blank observation sheet. The headline reads “Every reduction needs a record,” followed by glucose support, concurrent therapy and follow-up. No actual patient or study data appear.
AI-generated illustrative clinical scene. This is not an actual upLIFT site, participant, device record or verified study workflow.
Glucose supportTraceable change
The endpoint measures a reduction in infusion requirements. The clinical interpretation also needs treatment context and follow-up.

What the source reported

Rezolute’s preliminary upLIFT evaluation reported 13 responders among 16 participants and 12 who stopped IV glucose. Three remained in the pivotal period; completed-study analysis is expected by mid-December. No drug-related safety findings were attributed to ersodetug to date. The therapy remains investigational. [1]

Tumor hyperinsulinism can arise from insulin or related substances produced by certain tumors. Ersodetug is a monoclonal antibody designed to modulate insulin-receptor activity. Its development question concerns the metabolic effect of those signals. Control of hypoglycemia and control of the underlying cancer are distinct outcomes. [2, 3]

Reducing continuous glucose-support requirements could ease treatment burden. That potential deserves attention even without a tumor-response endpoint. Earlier discharge, improved quality of life and survival benefit each require separate evidence; they cannot be assigned from an infusion change alone.

Study design shapes the interpretation

upLIFT is an open-label, single-arm Phase 3 study evaluating add-on treatment against participants’ baseline requirements. The pivotal treatment period lasts eight weeks. Its response criterion is a reduction of at least 50% in glucose infusion rate. Participants continue usual hypoglycemia care, and physicians may adjust prescribed anticancer treatment. [2, 4]

There is no concurrent randomized comparison. Reliable context around changes in supportive care is therefore important when reviewing the observed response. This is an interpretation of the design, not a finding that the study failed to capture that context.

A lower infusion rate needs a clinical context

Lampgen would begin an operational review by asking whether the documented concentration, infusion rate, assessment timing and calculation basis allow a reviewer to understand the support requirement. Any required source-to-endpoint reconciliation should follow the actual protocol and analysis plan.

Relevant changes in nutrition, hypoglycemia medicines, rescue support and anticancer therapy should remain visible to the responsible clinical and statistical reviewers. A change may be medically appropriate and still need a clear timeline for interpretation. These are proposed practices, not a description of a verified upLIFT monitoring plan.

Keep the regulatory programs separate

The congenital-HI sunRIZE trial is a different evidence package. Rezolute’s November 5 filing says it missed its primary and key secondary endpoints at the defined evaluation window. The filing describes a recommended pre-BLA meeting and explicitly says FDA had not determined approvability. [3]

The tumor-HI result does not establish congenital-HI efficacy or FDA approval. Teams communicating the program should preserve the indication, study design and endpoint attached to each claim.

What this means for trial teams

Make the first review question concrete. Can the site record explain the observed reduction without guessing what happened between assessments? The CRA can investigate missing or conflicting documentation and escalate through the agreed monitoring process. The investigator directs clinical care; medical and statistical teams retain their decisions.

Use SIGNAL™ where the pattern requires action. If the same documentation gap appears repeatedly, investigate whether its cause lies in the worksheet, training, source access or handoff. Name the responsible owner, agree the corrective action and examine subsequent records. These are Lampgen’s proposed operational checks, not reported study deficiencies.

Follow the person after support changes. Review completeness of required glucose assessments, rescue-treatment records, safety follow-up and patient-reported measures. Stopping glucose support is one milestone. Whether control lasts and the participant experiences less burden must be assessed directly. Small samples also limit what can be concluded about uncommon or delayed harms.

Lampgen Clinical Research helps sponsors define oncology CRA and clinical-operations staffing needs around work that requires clear ownership. Teams can use the linked services information to scope those responsibilities.

Analysis by Tommy Lampley, Jr., M.S., Founder, Lampgen Clinical Research. Published November 13, 2026. The accompanying visual is an AI-generated illustrative clinical scene and contains no actual patient or study data.

Sources

  1. Rezolute — preliminary Phase 3 upLIFT update, November 13, 2026; evaluation dated November 5
  2. UK Health Research Authority — RZ358-302 study design and research summary
  3. Rezolute — Form 10-Q, November 5, 2026; mechanism and congenital-HI regulatory context
  4. ClinicalTrials.gov — upLIFT, NCT06881992
  5. Fierce Biotech, Nick Paul Taylor — reporting on upLIFT and the FDA discussion, November 13, 2026
  6. Lampgen — oncology CRA staffing responsibilities
  7. Lampgen — worked SIGNAL™ monitoring case

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?